Crystal's MCW Coder Hub🧬 ICD-10-CM T49.5X5A — Adverse Effect of Ophthalmological Drugs, Initial Encounter
Billable Code Confirmed — 7 Characters Complete
ICD-10 CM T49.5X5A is a valid, billable 7-character ICD-10-CM code for FY2025. Structure:
T49(topical agents/ophthalmic drugs) +.5(ophthalmological preparations) +X(placeholder) +5(adverse effect) +A(initial encounter). Complete and current.
🚨 NEVER SEQUENCE T49.5X5A AS PRINCIPAL DIAGNOSIS
🚨 VAULT CORRECTION — T38 Excludes1 Changes Our Glaucoma Drop Coding
T38.0 EXCLUDES1: “glucocorticoids, topically used (T49.-)” T49 INCLUDES: “glucocorticoids, topically used”
This is an Excludes1 — meaning these two codes CANNOT be used together for the same drug encounter. They are mutually exclusive based on route of administration.
Drug Route Correct T-Code Topical ophthalmic drops (Pred Forte, Lotemax, FML) T49.5X5A ← here Intravitreal injection (Ozurdex, Kenalog intravitreal) T49.5X5A ← here Oral (prednisone, methylprednisolone tabs) T38.0X5A IV/IM (Solu-Medrol, Kenalog IM) T38.0X5A Inhaled/intranasal (fluticasone, budesonide) T38.0X5A Update all glaucoma notes accordingly for topical/intravitreal steroid scenarios.
🔍 Code Description
ICD-10 CM T49.5X5A classifies the adverse effect of ophthalmological drugs and preparations at the initial encounter — the mandatory secondary T-code identifying the drug category responsible when a correctly prescribed and correctly administered ophthalmic medication causes a harmful reaction. This code covers the entire universe of topical eye medications — glaucoma drops (prostaglandins, beta-blockers, alpha agonists, CAIs, rho kinase inhibitors), topical ophthalmic steroids, antibiotics, antiviral agents, antifungals, and intravitreal preparations — whenever a harmful effect results from their appropriate use.
ICD-10 CM T49.5X5A is the ophthalmic-specific companion code to the condition it causes — just as T38.0X5A serves systemic steroid adverse effects, T49.5X5A serves topical and ophthalmological drug adverse effects. The critical ICD-10-CM tabular instruction is the Excludes1 on T38.0 confirming that topically used glucocorticoids — Pred Forte, Lotemax, FML, dexamethasone drops — belong here under T49, not T38.
🔑 The T38 vs. T49 Split — The Most Important Concept in This Note
Steroid Route = T-Code Destination
This distinction is critical for every steroid-induced glaucoma and steroid-induced cataract case in the vault. The same class of drug — glucocorticoids — maps to two DIFFERENT T-code categories based entirely on route of administration, and they carry an Excludes1 relationship meaning they cannot be coded simultaneously for the same drug.
The Complete Steroid Route → T-Code Map
| Steroid | Route | T-Code | Rationale |
|---|---|---|---|
| Prednisolone acetate 1% (Pred Forte) | Topical ophthalmic drop | T49.5X5A | Topically used glucocorticoid → T49 per Excludes1 [web:261] |
| Loteprednol (Lotemax) | Topical ophthalmic drop | T49.5X5A | Topically used glucocorticoid → T49 |
| Fluorometholone (FML) | Topical ophthalmic drop | T49.5X5A | Topically used glucocorticoid → T49 |
| Dexamethasone eye drops | Topical ophthalmic drop | T49.5X5A | Topically used glucocorticoid → T49 |
| Rimexolone (Vexol) | Topical ophthalmic drop | T49.5X5A | Topically used glucocorticoid → T49 |
| Difluprednate (Durezol) | Topical ophthalmic drop | T49.5X5A | Topically used glucocorticoid → T49 |
| Dexamethasone intravitreal (Ozurdex) | Intravitreal implant | T49.5X5A | Ophthalmological preparation → T49.5 |
| Triamcinolone acetonide (Kenalog, Triesence) | Intravitreal / sub-Tenon | T49.5X5A | Ophthalmological preparation → T49.5 |
| Fluocinolone acetonide (Iluvien, Retisert) | Intravitreal implant | T49.5X5A | Ophthalmological preparation → T49.5 |
| Prednisone | Oral | T38.0X5A | Systemic glucocorticoid — NOT topically used |
| Methylprednisolone (Medrol) | Oral / IV / IM | T38.0X5A | Systemic — NOT topically used |
| Fluticasone (Flonase, Flovent) | Inhaled / intranasal | T38.0X5A | Not ophthalmological preparation |
| Budesonide (Pulmicort) | Inhaled | T38.0X5A | Not ophthalmological preparation |
| Betamethasone (epidural/joint) | Injection, non-ophthalmic | T38.0X5A | Not ophthalmological route |
The Quick Test — "Is it going IN or ON the eye directly?"
📊 All Ophthalmological Drugs Under T49.5X5A
T49.5 covers all ophthalmological drugs and preparations — not just steroids. Every drug that is classified as an ophthalmic preparation maps here when an adverse effect occurs from correct use.
Glaucoma Medications — All Routes to T49.5X5A
| Drug Class | Examples | Adverse Effects Coding to T49.5X5A |
|---|---|---|
| Prostaglandin analogues | Latanoprost (Xalatan), bimatoprost (Lumigan), travoprost (Travatan Z), tafluprost (Zioptan), latanoprostene bunod (Vyzulta) | Iris color change (H21.xx), periorbital fat atrophy, eyelash growth (DUES), prostaglandin-associated periorbitopathy |
| Topical beta-blockers | Timolol (Timoptic), betaxolol (Betoptic), levobunolol (Betagan), carteolol | Bradycardia, bronchospasm, depression, fatigue — systemic absorption from topical → T49.5X5A not T-codes for cardiac drugs |
| Alpha-2 agonists | Brimonidine (Alphagan P), apraclonidine | Allergic follicular conjunctivitis (H10.1x), CNS depression (pediatric), dry mouth |
| Topical CAIs | Dorzolamide (Trusopt), brinzolamide (Azopt) | Superficial punctate keratitis (H16.14x), allergic reaction, metallic taste |
| Rho kinase inhibitors | Netarsudil (Rhopressa) | Conjunctival hyperemia, cornea verticillata (H18.45x), subconjunctival hemorrhage |
| Combination drops | Cosopt (dorzol/timolol), Combigan (brimoni/timolol), Rocklatan (neta/latan) | Combined adverse effects of component drugs |
| Topical ophthalmic steroids | Pred Forte, Lotemax, FML, Durezol, dexamethasone drops | IOP elevation → glaucoma (H40.61X-), PSC cataract (H26.13), delayed wound healing |
| Topical antibiotics | Moxifloxacin (Vigamox), tobramycin, erythromycin, azithromycin, ciprofloxacin | Allergic conjunctivitis, corneal toxicity, superficial punctate keratitis |
| Topical antivirals | Trifluridine (Viroptic), ganciclovir gel | Punctate keratopathy, corneal epithelial toxicity |
| Topical antifungals | Natamycin (Natacyn), voriconazole ophthalmic | Ocular irritation, corneal toxicity |
| Topical NSAIDs | Ketorolac (Acular), bromfenac (Prolensa), nepafenac (Nevanac) | Corneal melt (rare, serious) (H18.xx), superficial punctate keratitis |
| Topical cycloplegics/mydriatics | Atropine, cyclopentolate, tropicamide, phenylephrine | Angle-closure precipitation (H40.23x), photophobia, systemic anticholinergic |
| Intravitreal anti-VEGF | Bevacizumab (Avastin), ranibizumab (Lucentis), aflibercept (Eylea), faricimab (Vabysmo), brolucizumab (Beovu) | Endophthalmitis (H44.00x), retinal detachment, IOP spike, RPE tear, thromboembolic events |
| Intravitreal steroids | Ozurdex (dexamethasone implant), triamcinolone, Iluvien, Retisert | IOP elevation → glaucoma (H40.61X-), PSC cataract (H26.13) |
| Ocular surface — artificial tears/preservatives | BAK-preserved drops | BAK toxicity — superficial punctate keratitis, dry eye exacerbation |
💊 T49.5X5A vs. T38.0X5A — The Vault Update
Updating Our Glaucoma Notes — The Correct T-Code by Clinical Scenario
| Clinical Scenario | H40.6x Glaucoma Code | Correct T-Code |
|---|---|---|
| SIG from topical Pred Forte post-op | H40.61X_ | T49.5X5A ← NOT T38 |
| SIG from Ozurdex for DME | H40.61X_ | T49.5X5A ← NOT T38 |
| SIG from intravitreal triamcinolone | H40.61X_ | T49.5X5A ← NOT T38 |
| SIG from oral prednisone for RA | H40.61X_ | T38.0X5A — systemic |
| SIG from inhaled fluticasone | H40.61X_ | T38.0X5A — systemic |
| SIG from IV methylprednisolone | H40.61X_ | T38.0X5A — systemic |
| PSC cataract from Pred Forte drops | H26.13 | T49.5X5A ← NOT T38 |
| PSC cataract from oral prednisone | H26.13 | T38.0X5A — systemic |
| Timolol bradycardia from glaucoma drop | R00.1 | T49.5X5A — ophthalmic drug |
| Brimonidine allergy conjunctivitis | H10.1x | T49.5X5A — ophthalmic drug |
| Dorzolamide keratitis | H16.14x | T49.5X5A — ophthalmic drug |
| Prostaglandin iris darkening | H21.xx | T49.5X5A — ophthalmic drug |
| Anti-VEGF endophthalmitis post-injection | H44.00x | T49.5X5A — ophthalmic drug |
📊 7th Character — Same Rules as T38.0X5A
| 7th Character | Code | Meaning | When to Use |
|---|---|---|---|
| A | T49.5X5A ← THIS CODE | Active treatment phase | First diagnosis; surgical intervention; new treatment initiation for the adverse effect |
| D | T49.5X5D | Routine follow-up / aftercare | All ongoing monitoring visits |
| S | T49.5X5S | Sequela — late effect | Condition persists after the drug is discontinued |
Real-World 7th Character Timeline — Topical Steroid Glaucoma
| Visit | Clinical Event | T-Code |
|---|---|---|
| Visit 1 | Post-op Pred Forte → IOP 38 mmHg → SIG newly diagnosed → starting timolol | T49.5X5A ← Initial |
| Visit 2 | 6-week check — IOP on timolol, stable | T49.5X5D ← Subsequent |
| Visit 3 | SLT performed — new active treatment | T49.5X5A ← Initial (new treatment) |
| Visit 4 | Post-SLT monitoring — IOP stable | T49.5X5D ← Subsequent |
| Visit 5 | Pred Forte stopped, glaucoma persists long-term | T49.5X5S ← Sequela |
🔗 Related ICD-10-CM Codes
T49.5X5 Family — All Encounters
| Code | Description | Use When |
|---|---|---|
| T49.5X5A | Adverse effect of ophthalmological drugs, initial encounter ← THIS CODE | First diagnosis; new active treatment |
| T49.5X5D | Adverse effect of ophthalmological drugs, subsequent encounter | All routine monitoring/follow-up visits |
| T49.5X5S | Adverse effect of ophthalmological drugs, sequela | Late effect after drug discontinued |
T49.5X Poisoning Family — For Reference
| Code | Description |
|---|---|
| T49.5X1A | Poisoning by ophthalmological drugs, accidental |
| T49.5X2A | Poisoning by ophthalmological drugs, intentional self-harm |
| T49.5X3A | Poisoning by ophthalmological drugs, assault |
| T49.5X4A | Poisoning by ophthalmological drugs, undetermined |
| T49.5X6A | Underdosing of ophthalmological drugs |
T49 Broader Family — Other Ophthalmic/ENT/Dental Routes
| Code | Description |
|---|---|
| T49.0X5A | Adverse effect of antifungals (topical skin) |
| T49.3X5A | Adverse effect of emollients, demulcents, protectants |
| T49.6X5A | Adverse effect of otorhinolaryngological drugs (ENT drops, nasal sprays) |
| T49.7X5A | Adverse effect of dental drugs |
Conditions Commonly Requiring T49.5X5A as Mandatory Additional Code
| Condition Code | Description |
|---|---|
| H40.61X1-H40.63X4 | Drug-induced glaucoma — when TOPICAL/INTRAVITREAL steroid is the cause |
| H26.13 | PSC cataract — when topical steroid drops are the cause |
| H44.00x | Endophthalmitis — adverse effect of intravitreal injection |
| H10.1x | Acute atopic conjunctivitis — brimonidine allergy |
| H16.14x | Punctate keratitis — dorzolamide, topical NSAID toxicity |
| R00.1 | Bradycardia — topical timolol systemic absorption |
| J45.x | Bronchospasm — topical timolol systemic absorption |
| H21.xx | Iris changes — prostaglandin-associated iris darkening |
| H18.45x | Cornea verticillata — netarsudil adverse effect |
💊 Coding Scenarios
Scenario 1 — Topical Pred Forte SIG Post-Cataract Surgery (T49.5X5A ← NOT T38)
Clinical Vignette: A 71-year-old male underwent uneventful right cataract surgery. Postoperatively placed on prednisolone acetate 1% (Pred Forte) QID × 4 weeks. At 3-week post-op visit: IOP OD 36 mmHg — elevated from baseline of 14 mmHg. OCT RNFL OD: normal — no glaucomatous damage yet. HVF deferred — IOP spike being managed. Physician: “New steroid-induced IOP elevation — early drug-induced glaucoma OD from Pred Forte. Tapering Pred Forte, adding timolol OD.”
ICD-10-CM:
- H40.61X1 — Glaucoma secondary to drugs, right eye, mild stage (Code First — the harm)
- T49.5X5A — Adverse effect of ophthalmological drugs, initial encounter (Pred Forte is TOPICAL ophthalmic → T49, NOT T38)
This Is NOT T38.0X5A — Pred Forte Is a Topically Used Glucocorticoid
Scenario 2 — Ozurdex Intravitreal Implant → SIG (T49.5X5A)
Clinical Vignette: A 65-year-old female with right eye BRVO and CME received Ozurdex (dexamethasone intravitreal implant) 4 months ago. Today: IOP OD 28 mmHg (baseline 15). HVF OD: MD -7.4 dB — moderate field loss. OCT RNFL OD: moderate thinning. Physician: “Drug-induced glaucoma OD, moderate stage — secondary to Ozurdex implant. Starting latanoprost OD.”
ICD-10-CM:
- H40.61X2 — Glaucoma secondary to drugs, right eye, moderate stage (Code First)
- T49.5X5A — Adverse effect of ophthalmological drugs, initial encounter (Ozurdex is an INTRAVITREAL ophthalmological preparation → T49.5)
- H34.811 — BRVO, right eye (underlying condition treated with Ozurdex)
Scenario 3 — Timolol Bradycardia — Systemic Adverse Effect of Topical Glaucoma Drop
Clinical Vignette: A 73-year-old male on timolol 0.5% BID OU for POAG presents reporting fatigue and dizziness. Pulse: 46 bpm. EKG: sinus bradycardia. Cardiologist confirms timolol-related bradycardia. Timolol discontinued — switched to latanoprost.
ICD-10-CM:
- R00.1 — Bradycardia (Code First — the adverse effect, the HARM)
- T49.5X5A — Adverse effect of ophthalmological drugs, initial encounter (timolol eye drop is an ophthalmological preparation — even though the effect is cardiac, the drug source is T49.5)
Systemic Effect of a Topical Ophthalmic Drug → Still T49.5X5A
When a glaucoma drop (timolol, brimonidine, dorzolamide) causes a systemic adverse effect (bradycardia, bronchospasm, CNS depression), the T-code is still T49.5X5A — because the DRUG is an ophthalmological preparation. The T-code classifies the drug, not the organ system affected. The cardiac beta-blocker T-codes (T44.7x5) apply to systemic beta-blocker prescriptions — not to timolol eye drops.
Scenario 4 — Anti-VEGF Injection → Endophthalmitis (T49.5X5A)
Clinical Vignette: A 69-year-old female received intravitreal aflibercept (Eylea) injection for wet AMD right eye. 3 days post-injection presents with pain, decreased vision, hypopyon OD. Diagnosis: post-injection endophthalmitis OD.
ICD-10-CM:
- H44.001 — Endophthalmitis, unspecified, right eye (Code First — the harm)
- T49.5X5A — Adverse effect of ophthalmological drugs, initial encounter (Eylea is intravitreal ophthalmological preparation — correctly prescribed, correctly administered)
- H35.3211 — Wet AMD, right eye, active CNV (underlying condition treated)
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | |
|---|---|
| ❌ | Never use T38.0X5A for topical ophthalmic steroids — T38.0 Excludes1 sends topically used glucocorticoids to T49 [web:261][web:268] |
| ❌ | Never sequence T49.5X5A as principal diagnosis — condition caused is always first; T-code is additional [web:263] |
| ❌ | Never use T49.5X5A for systemic steroids — oral/IV/inhaled glucocorticoids → T38.0X5A |
| ❌ | Never use T49.5X5A for poisoning scenarios — wrong drug, overdose → T49.5X1A-T49.5X4A |
| ❌ | Never assume systemic beta-blocker T-code for timolol eye drops — the drug is ophthalmological → T49.5X5A regardless of where the adverse effect manifests |
| ✅ | Topical or intravitreal steroid → T49.5X5A — Pred Forte, Lotemax, FML, Ozurdex, Kenalog intravitreal, Iluvien, Retisert [web:261] |
| ✅ | Systemic/inhaled steroid → T38.0X5A — oral prednisone, IV Solu-Medrol, inhaled fluticasone/budesonide [web:268] |
| ✅ | All glaucoma drops → T49.5X5A — prostaglandins, beta-blockers, alpha agonists, CAIs, ROCK inhibitors |
| ✅ | All intravitreal drugs → T49.5X5A — anti-VEGF injections, intravitreal steroid implants |
| ✅ | 7th character rules are identical to T38.0X5A — A for active/initial, D for follow-up, S for sequela |
| ✅ | One T49.5X5D covers all ophthalmic drug adverse effects at a follow-up visit when multiple drugs are implicated |
| ✅ | T49.5X5A can appear multiple times in a patient’s care — resets with each new active treatment episode |
📚 Sources
1. AAPC Codify. “T49.5X5A — Adverse effect of ophthalmological drugs and preparations, initial encounter.” T49 Includes: “poisoning by, adverse effect of and underdosing of glucocorticoids, topically used.” [web:261]
2. ICDList.com. “T49.5X5A — Adverse effect of ophthalmological drugs and preparations, initial encounter.” Confirmed billable FY2025. Unacceptable as principal diagnosis confirmed. [web:263]
3. AAPC Codify. “T38.0X5A — Adverse effect of glucocorticoids and synthetic analogues, initial encounter.” T38.0 Excludes1: “glucocorticoids, topically used (T49.-)” — confirmed Excludes1 directing topically used glucocorticoids exclusively to T49 family. [web:268]
4. PMC / NIH. “Managing adverse effects of glaucoma medications.” Clinical overview of systemic adverse effects from topical glaucoma drops — timolol (bradycardia, bronchospasm), brimonidine (CNS depression, allergy), dorzolamide (keratitis), prostaglandins (iris darkening, DUES). [web:266]
5. ICD-10-CM Official Guidelines for Coding and Reporting, FY2025. Section I.C.19.e — Adverse Effects sequencing: condition first, T-code additional. 7th character definitions: A (initial/active treatment), D (subsequent/routine), S (sequela).